文章基本信息

标题：Dapsone is an anticatalysis for Alzheimer’s disease exacerbation
本地全文：下载
作者：Jong Hoon Lee ; Badar Kanwar ; Chul Joong Lee 等
期刊名称：iScience
印刷版ISSN：2589-0042
出版年度：2022
卷号：25
期号：5
页码：1-15
DOI：10.1016/j.isci.2022.104274
语种：English
出版社：Elsevier
摘要：SummaryBrain inflammation generally accelerates neurodegeneration. Alzheimer’s disease (AD) triggers an innate immune response by activating a cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway. Our study investigated patients with leprosy and AD. They were treated with dapsone (4,4′-diaminodiphenyl sulfone, DDS) as a neuroinflammasome competitor and cGAS/STING pathway inhibitor. Four groups were defined: Treatment (T) 1: DDS prescribed AD diagnosed, T 2: DDS prescribed AD undiagnosed, T 3 DDS unprescribed AD diagnosed, and T 4: DDS unprescribed AD undiagnosed. Dapsone effects on AD can be clearly distinguished according to dapsone presence or absence. T1:T3 proved that the incidence of AD was significantly reduced by dapsone. T2:T3 proved that the prevalence of AD was significantly high without dapsone. T1:T4 proved that the prevalence decreased when taking dapsone. Our study demonstrates that dapsone can prevent AD exacerbation and may represent a preventive therapeutic option for exacerbated AD.Graphical abstractDisplay OmittedHighlights•Brain inflammation generally accelerates neurodegeneration•Dementia Management Act separates dapsone-taking groups at Sorok Island•The analysis of all from 2005 to 2020 was evaluated based on a p value of 0.05•Dapsone is a preventive therapeutic option for exacerbated Alzheimer’s diseaseHealth sciences; Biological sciences; Neuroscience; Clinical neuroscience